NEW YORK (GenomeWeb) – Bio-Techne has signed a deal to gain access to B-MoGen Biotechnologies' gene-editing technology, the companies announced today. As part of the arrangement, Bio-Techne has also made an unspecified seed investment in B-MoGen.

Specific details about the technology were not disclosed, but B-MoGen offers genome modification services that use targeted nucleases to delete genes, exons, or genomic regions, or to insert specific sequences into the genome. The company has also filed a patent application on a single-step method for isolating gene-edited cells.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.